Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Hurdles ahead for whole genome sequencing

17 March 2014

By Chee Hoe Low

Appeared in BioNews 746

Genome sequencing technology struggles to capture the complete genome accurately and reliably, a small study has found.

Many obstacles need to be overcome before whole genome sequencing (WGS), a DNA-evaluating technique that detects genetic disease risks, can be used routinely in clinics, say the researchers.

'We need to be very honest about what we can and cannot do at this point in time', said Dr Euan Ashley, co-author of the research and associate professor of medicine at Stanford University, California. 'It's clear that if we sequence enough cases, we can change someone's life. But with this opportunity comes the responsibility to do this right'.

To observe how WGS technique works in a real-life clinical setting, the researchers analysed the whole genomes of 12 healthy volunteers, and noted of the accuracy of the sequencing, the time and cost it took to analyse the genome data manually, and the clinical action prompted by the findings.

Two genome sequencing service providers were used for the research: Illumina and Complete Genomics, both based in California. Researchers found that both providers failed to capture ten to 19 percent of genes associated with inherited diseases, making it easy to miss out harmful mutations. Both providers were not always consistent, with the tests disagreeing on around two-thirds of gene mutations involving the addition or deletion of DNA.

Nevertheless, the researchers found the cost of WGS to be lower than expected. Dr Ashley estimated the total cost of sequencing the genome of one patient to be at US $11,000, with follow-up testing costing less than $1,000.

The study also found that interpreting the full genome data requires a significant amount of manpower and is time-consuming. Researchers spent about one hour interpreting each genome variant found, bringing the total cost to $15,000 per patient.

The WGS technique, if successful, could potentially be used routinely to detect risks of unusual, rare genetic diseases, and predict how patients might respond to treatments. Companies now aim to offer WGS services for $1,000 (reported in BioNews 738), but this pilot research shows that more work needs to be done before it can be implemented in the clinic.

'Our hope is that the identification of specific hurdles will allow researchers in this field to focus their efforts on overcoming them to make this technique clinically useful', said Dr Ashley.

'There are many steps that have to be worked out to ensure that we gain the most health-care benefit', said Dr William Gregory Feero of Maine Dartmouth Family Medicine Residency in an editorial accompanying the research.

SOURCES & REFERENCES
Reuters | 11 March 2014
 
Journal of the American Medical Association | 12 March 2014
 
Journal of the American Medical Association | 12 March 2014
 
Nature News | 11 March 2014
 
The Scientist | 11 March 2014
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 October 2014 - by Sean Byrne 
Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce...

28 October 2013 - by Dr Lucy Freem 
A three-year joint project to sequence the genomes of 10,000 rare disease patients has been announced by the University of Cambridge, Genomics England and Illumina...
15 July 2013 - by Richard Fadok 
Whole genome sequencing suggests that around half of all people with autism may be carriers of genes already associated with the condition...
10 December 2012 - by Antony Blackburn-Starza 
The UK Government has announced plans that will allow 100,000 NHS patients to have their whole genome sequenced over the next three to five years, as part of a move to boost economic growth in the life sciences industry...
19 November 2012 - by Emma Stoye 
Genetic sequencing has been used to track and halt an outbreak of MRSA at an NHS hospital in Cambridge....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation